Breathe Well Live Well
|
Positive Phase II Asthma Clinical Trial Data
SYS-CON Media (press release) This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma … |
View full post on asthma – Google News
|
Oops, Our Data Weren't That Good
DailyFinance By Brian Orelli, The Motley Fool Targacept (NAS: TRGT) was a little off target with its initial analysis that its phase 2 trial testing TC-6987 in asthma passed both its co-primary endpoints. It's kind of like being off with earnings estimates, … Targacept reports error in asthma study UPDATE Targacept loses big shareholder, finds error in previous study |
View full post on asthma – Google News
|
Mixed Data for Glaxo & THRX Drug
Zacks.com GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced top-line data from phase III studies conducted with their pipeline candidate, Relovair, for chronic obstructive pulmonary disease (COPD) and asthma. Relovair is a combination of … Breathe Easy: Program Complete, Data Solid |
View full post on asthma – Google News
|
Biota Reports Positive Phase IIb Data For Asthmatic Patients With HRV Infection
NASDAQ The Phase II multicenter, randomized, double-blind, placebo controlled study in asthmatic adults with symptomatic, naturally acquired human rhinovirus infection was conducted over two consecutive seasons in 48 centers in the US Subjects received either … Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human … |
View full post on asthma – Google News
|
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human …
MarketWatch (press release) "While the clinical link between HRV infection and loss of asthma control is now widely accepted, Biota is the first company to evaluate the use of an antiviral to treat the infection in asthmatics. This has the potential to be of considerable benefit … |
View full post on asthma – Google News
|
Targacept reports mixed data from two trials
Reuters * Says asthma trial meets main goals * Says diabetes trial did not meet main goal * Targacept drops development of drug for diabetes March 27 (Reuters) – Targacept said an experimental drug proved effective in a mid-stage asthma trial, but failed to … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Targacept Dropping Development Of Diabetes Drug; Shares Fall Targacept Reports Top-Line Results From 2 Exploratory Phase 2 Studies Of TC-6987 |
View full post on asthma – Google News
|
GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma
Genetic Engineering News GlaxoSmithKline (GSK) and Theravance are reporting mostly positive results from two studies for Relovair in chronic obstructive pulmonary disease (COPD) and asthma. Relovair met its primary endpoint in one of two replicate studies in COPD comparing it … GSK and Theravance Announce Completion of the Relovair(TM)* Registrational … GSK lung drug has mixed results but filing on track GSK's Relovair on track for COPD drug filing; talks on asthma in US ongoing |
View full post on asthma – Google News
|
KALBITOR(R) (ecallantide) Data Presented at American Academy of Allergy …
MarketWatch (press release) (NASDAQ:DYAX) today announced the presentation of data from KALBITOR(R) (ecallantide) clinical studies in hereditary angioedema (HAE) at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in Orlando, Florida. |
View full post on asthma – Google News
|
KALBITOR (ecallantide) Data in HAE Presented at the American College of …
PharmaLive.com (press release) (NASDAQ: DYAX) announced today that two oral and two poster presentations featuring KALBITOR® (ecallantide) data in hereditary angioedema (HAE) were presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held … KALBITOR(R) (ecallantide) Data in HAE Presented at the American College of … |
View full post on asthma – Google News
|
KALBITOR® (ecallantide) Data in HAE Presented at the American College of …
Business Wire (press release) (NASDAQ: DYAX) announced today that two oral and two poster presentations featuring KALBITOR ® (ecallantide) data in hereditary angioedema (HAE) were presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held … KALBITOR(R) (ecallantide) Data in HAE Presented at the American College of … |
View full post on asthma – Google News